ERBB2 and breast carcinoma: High positive expression rate and strong expression intensity of Topo II protein in basal-like and HER2+ breast cancer suggested that anthracycline drugs were sensitive to basal-like and HER2+ breast cancers, which was consistent with previous reports19,20.